Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

Sponsor
Guangzhou Institute of Respiratory Disease
Study ID
NCT06739928
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Small Cell Lung Cancer Extensive Stage

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a prospective, randomized, parallel, multicenter phase II study aimed at evaluating the efficacy and safety of irinotecan liposome (II) or etoposide combined with adebrelimab and carboplatin as first-line treatment for extensive stage small cell lung cancer. The primary endpoint of the study was the 1-year overall survival rate.

Key Dates

Start date
Jan 1, 2025
Status verified
Dec 2024
Primary completion
Jun 30, 2026
Completion
Dec 30, 2027

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Irinotecan liposome (II)+adebrelimab+carboplatin
    The patient received treatment with Irinotecan liposome (II), adebrelimab, and carboplatin.
  • Other: etoposide+adebrelimab+carboplatin
    The patient received treatment with etoposide, adebrelimab, and carboplatin.

Primary Outcome Measure

1-year OS rate [ Time Frame: 1 year ]

Central Contacts

Related Studies